S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
Log in
NASDAQ:MRNS

Marinus Pharmaceuticals News Headlines

$11.15
+0.45 (+4.21 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$10.84
Now: $11.15
$12.98
50-Day Range
$6.96
MA: $8.59
$13.84
52-Week Range
$4.04
Now: $11.15
$16.28
Volume2.32 million shs
Average Volume623,707 shs
Market Capitalization$340.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2

Headlines

Marinus Pharmaceuticals (NASDAQ MRNS) News Headlines Today

Source:
DateHeadline
Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by LADENBURG THALM/SH SHMarinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by LADENBURG THALM/SH SH
marketbeat.com - September 25 at 7:53 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $26.00Marinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $26.00
americanbankingnews.com - September 25 at 10:45 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by LADENBURG THALM/SH SHMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by LADENBURG THALM/SH SH
americanbankingnews.com - September 25 at 10:45 AM
Marinus closing in on launch of pivotal study of ganaxolone in life-threatening type of epilepsyMarinus closing in on launch of pivotal study of ganaxolone in life-threatening type of epilepsy
seekingalpha.com - September 24 at 5:52 PM
Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Raised to $28.00Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Raised to $28.00
americanbankingnews.com - September 23 at 9:39 AM
Marinus reverse split shares 1:4Marinus reverse split shares 1:4
seekingalpha.com - September 22 at 2:36 PM
Marinus Announces One-for-Four Reverse Stock SplitMarinus Announces One-for-Four Reverse Stock Split
finance.yahoo.com - September 22 at 9:32 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Price Down 7.2%Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Price Down 7.2%
americanbankingnews.com - September 21 at 9:37 PM
Is Marinus Stock Still Worth Buying After Its 50% Rally? This Analyst Says YesIs Marinus Stock Still Worth Buying After Its 50% Rally? This Analyst Says Yes
finance.yahoo.com - September 16 at 12:14 AM
Looking Into Marinus Pharmaceuticalss Return On Capital EmployedLooking Into Marinus Pharmaceuticals's Return On Capital Employed
benzinga.com - September 15 at 7:13 PM
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Price Up 51.7% on Analyst UpgradeMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Price Up 51.7% on Analyst Upgrade
americanbankingnews.com - September 15 at 6:45 PM
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Sees Significant Growth in Short InterestMarinus Pharmaceuticals Inc (NASDAQ:MRNS) Sees Significant Growth in Short Interest
americanbankingnews.com - September 15 at 5:52 PM
Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Raised to $4.00Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Raised to $4.00
americanbankingnews.com - September 15 at 4:20 PM
Why This Epilepsy Study Is Huge for Marinus PharmaceuticalsWhy This Epilepsy Study Is Huge for Marinus Pharmaceuticals
msn.com - September 15 at 2:13 PM
Why Marinus Pharma Shares Are Rocketing HigherWhy Marinus Pharma Shares Are Rocketing Higher
msn.com - September 15 at 2:13 PM
Looking Into Marinus Pharmaceuticals's Return On Capital EmployedLooking Into Marinus Pharmaceuticals's Return On Capital Employed
finance.yahoo.com - September 15 at 2:13 PM
Marinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in SessionMarinus Pharmaceuticals (MRNS) Soars: Stock Adds 5.5% in Session
finance.yahoo.com - September 15 at 2:13 PM
Nasdaq Rises Despite Nikola Hit; Marinus SoarsNasdaq Rises Despite Nikola Hit; Marinus Soars
finance.yahoo.com - September 15 at 2:13 PM
Why Marinus Pharmaceuticals Stock Skyrocketed 80% Higher TodayWhy Marinus Pharmaceuticals Stock Skyrocketed 80% Higher Today
finance.yahoo.com - September 15 at 2:13 PM
Marinus Pharmaceuticals (NASDAQ:MRNS) Given New $7.00 Price Target at OppenheimerMarinus Pharmaceuticals (NASDAQ:MRNS) Given New $7.00 Price Target at Oppenheimer
americanbankingnews.com - September 15 at 11:01 AM
The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medicals IPOThe Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO
msn.com - September 15 at 9:12 AM
SVB Leerink Raises Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $8.00SVB Leerink Raises Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $8.00
americanbankingnews.com - September 15 at 9:11 AM
Jefferies Financial Group Raises Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $6.00Jefferies Financial Group Raises Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target to $6.00
americanbankingnews.com - September 15 at 8:28 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $8.00 at Cantor FitzgeraldMarinus Pharmaceuticals (NASDAQ:MRNS) PT Raised to $8.00 at Cantor Fitzgerald
americanbankingnews.com - September 15 at 8:28 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by HC WainwrightMarinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by HC Wainwright
americanbankingnews.com - September 15 at 8:28 AM
Marinus Rare Genetic Epilepsy Drug Meets Primary Goal In Late-Stage StudyMarinus' Rare Genetic Epilepsy Drug Meets Primary Goal In Late-Stage Study
nasdaq.com - September 14 at 11:11 PM
Marinus genetic epilepsy drug meets main goal of late-stage studyMarinus genetic epilepsy drug meets main goal of late-stage study
nasdaq.com - September 14 at 6:10 PM
Marinus Pharmas ganaxolone successful in pivot study in rare type of epilepsyMarinus Pharma's ganaxolone successful in pivot study in rare type of epilepsy
seekingalpha.com - September 14 at 6:10 PM
Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic EpilepsyGanaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy
finance.yahoo.com - September 14 at 6:10 PM
Stock Traders Purchase Large Volume of Marinus Pharmaceuticals Call Options (NASDAQ:MRNS)Stock Traders Purchase Large Volume of Marinus Pharmaceuticals Call Options (NASDAQ:MRNS)
americanbankingnews.com - September 14 at 5:29 PM
Marinus trades high on development contract with BARDAMarinus trades high on development contract with BARDA
seekingalpha.com - September 14 at 1:10 PM
Marinus signs government contract worth up to $51M to advance drug candidateMarinus signs government contract worth up to $51M to advance drug candidate
bizjournals.com - September 14 at 1:10 PM
Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Gap Up to $2.00Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Gap Up to $2.00
americanbankingnews.com - September 14 at 10:06 AM
Marinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent ExposureMarinus Awarded BARDA Contract to Develop IV Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure
finance.yahoo.com - September 14 at 8:09 AM
Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by OppenheimerMarinus Pharmaceuticals (NASDAQ:MRNS) Rating Reiterated by Oppenheimer
americanbankingnews.com - September 8 at 6:14 AM
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Given Average Recommendation of "Buy" by AnalystsMarinus Pharmaceuticals Inc (NASDAQ:MRNS) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - September 4 at 2:55 AM
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Expected to Announce Earnings of -$0.17 Per ShareMarinus Pharmaceuticals Inc (NASDAQ:MRNS) Expected to Announce Earnings of -$0.17 Per Share
americanbankingnews.com - September 2 at 2:20 AM
Marinus Pharmaceuticals EPS beats by $0.03Marinus Pharmaceuticals EPS beats by $0.03
seekingalpha.com - August 6 at 11:56 AM
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial ResultsMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
finance.yahoo.com - August 6 at 11:56 AM
Have Insiders Been Buying Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares?Have Insiders Been Buying Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares?
finance.yahoo.com - August 4 at 2:01 PM
Marinus Pharmas Ganaxolone nabs Rare Pediatric Disease tag for rare pediatric epilepsyMarinus Pharma's Ganaxolone nabs Rare Pediatric Disease tag for rare pediatric epilepsy
seekingalpha.com - July 30 at 2:41 PM
Why Marinus Pharmaceuticals Is Trading Higher TodayWhy Marinus Pharmaceuticals Is Trading Higher Today
finance.yahoo.com - July 30 at 2:41 PM
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)
finance.yahoo.com - July 30 at 9:41 AM
Marinus Pharmaceuticals Appoints Charles Austin to Board of DirectorsMarinus Pharmaceuticals Appoints Charles Austin to Board of Directors
finance.yahoo.com - July 29 at 5:27 PM
Marinus Pharma inks $60M stock sales deal with JMPMarinus Pharma inks $60M stock sales deal with JMP
seekingalpha.com - July 10 at 8:56 AM
Were Hedge Funds Right About Piling Into Marinus Pharmaceuticals Inc (MRNS)?Were Hedge Funds Right About Piling Into Marinus Pharmaceuticals Inc (MRNS)?
finance.yahoo.com - July 9 at 12:01 AM
Marinus Pharmaceuticals Provides Pipeline UpdateMarinus Pharmaceuticals Provides Pipeline Update
finance.yahoo.com - June 30 at 10:31 AM
Marinus Pharmaceuticals to Host Pipeline Update WebinarMarinus Pharmaceuticals to Host Pipeline Update Webinar
finance.yahoo.com - June 24 at 8:37 AM
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS ForumMarinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum
finance.yahoo.com - June 22 at 12:48 PM
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and SecretaryMarinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary
finance.yahoo.com - June 15 at 9:25 AM
Philadelphia-area life sciences companies expect to reel in more than $425M in a seven-day stretchPhiladelphia-area life sciences companies expect to reel in more than $425M in a seven-day stretch
www.bizjournals.com - June 3 at 2:21 PM
This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.